4 Questions – 4 Answers // Imaging in Clinical Trials
Mint Medical, Inc. Vice President of Clinical Trials, Kelie Luby Discusses Advances in Imaging Analysis in Clinical Trials and What’s Next for Mint Medical What advancements in imaging analysis…
Joint partnership between Mint Medical and Siemens Healthineers syngo.via
Siemens Healthineers and Mint Medical joined forces to accelerate imaging and result reporting software availability in hospitals when and where it is needed. This collaboration, announced at the…
Mint-Data for Personalized Medicine at Cancer Center in Tübingen/Germany
Compiling structured real-world-data from different medical disciplines, such as molecular genetics, laboratory medicine, pathology or radiology, to generate insights for specific diseases…
Number of Clinical Trials in Oncology has increased strongly during the last 10 years
Cancer cases and cancer related deaths continue to increase globally. While new cancer therapies are being identified offering new options for patients, many patients continue to live with cancer as…
New TNM- and RADS-Classification in mint Lesion
With the aid of various clinical reading templates, mint Lesion provides context-specific support in the application of established radiological criteria and guidelines for a more efficient…
New mint Lesion 3.4 Software presented at RSNA 2017
With mint Lesion 3.4, reproducible assessment and structured reporting of significant image observations are easier than ever. Numerous improvements and new functionalities related to the image…
ESOI/EORTC Workshop in Barcelona: Participants practice tumour response assessment using mint Lesion™
The autumn workshop of the European Society of Oncological Imaging (ESOI) and the European Organisation for Research and Treatment of Cancer (EORTC) is a 2.5 day interactive hands-on course that…
Mint Medical showcases MSK-Prototype at IMR 2017 in Hamburg
Mint Medical was one of the sponsors of the first Intensive course Musculoskeletal Radiology (IMR) which took place on September 8th and 9th 2017 in Hamburg. It was organized by the board of the AG…
A look ahead with mint Lesion 3.3
Mint Medical is pleased to announce the recent release of their software product version 3.3 of mint LesionTM which was completed during recent weeks. Mint Medical CEO, Dr. Matthias Baumhauer…
New iRECIST Oncologic Response Criteria already in clinical use at the University Medical Center – Tübingen, Germany
Shortly following the release of the new iRECIST- oncologic response criteria (Lancet Oncology, March 2017) the University Medical Center in Tübingen, Germany had already begun to implement this new…